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ALTITUD TINGGI DAN FAKTOR RISIKO LAIN- LAIN UNTUK PENYAKIT 
ARTERI KORONARI Dl YEMEN; PREVALENS, PRESENTASI KLINIKAL, 
KOMPLIKASI DAN PROGNOSIS 
ABSTRAK 
Tujuan utama tesis ini adalah untuk mengkaji prevalen faktor risiko, presentasi 
klinikal, komplikasi, prognosis penemuan ekokardiografi dan angiografi koronari 
di kalangan pesakit sindrom koronari akut (ACS) pada altitud tinggi dan rendah. 
Kajian pertama merupakan analisis penyemakan rekod retrospektif 
(Retrospective Review of Record) yang bertujuan untuk menganggarkan 
prevalens faktor-faktor risiko pada pesakit ACS di kedua-dua altitud. Ia juga 
menyiasat presentasi klinikal dan komplikasi pesakit ACS tersebut. Tujuh ratus 
enam puluh Iapan (768) pesakit ACS dari altitud tinggi dan rendah telah dikaji. 
Umur, jantina, altitud tempat tinggal, kadar denyutan jantung (HR), tekanan 
darah sistolik (SBP) dan tekanan darah diastolik (DBP) telah direkodkan. Faktor 
riwayat penyakit arteri koronari (CAD) telah disiasat. Komplikasi ACS sewaktu 
kemasukkan di dalam hospital juga telah direkodkan. Keputusan yang 
diperolehi kajian 1 menunjukkan bahawa umur purata pesakit ACS adalah lebih 
muda pada altitud tinggi apabila dibandingkan dengan penduduk di altitud 
rendah. Kadar jantung (HR), SBP dan DBP adalah lebih tinggi pada altitud 
tinggi. Pesakit altitud tinggi menunjukkan kelebihan hemoglobin (Hb), 
hematokrit, darah sel putih (WBC), kreatinin kinase (CK), kreatin kinase-
isoenzim (CK-MB), paras kolesterol, lipoprotein densiti rendah kolesterol (LDL-
C) dan triglesirid (TG). Prevalen riwayat hiperlipidemia dan CAD adalah lebih 
tinggi di kalangan pesakit altitud tinggi. Prevalen riwayat OM dan merokok 
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adalah tinggi dengan "border line significance" di kalangan pesakit altitud 
tinggi. Kerosakkan dinding kardiak yang dikesan oleh ekokardiografi adalah 
lebih tinggi untuk pesakit altitud tinggi. Fraksi ejeksi ventrikel kiri (LVEF) adalah 
lebih rendah di kalangan pesakit di altitud tinggi. Bilangan pesakit strok 
dikalangan pesakit altitud tinggi adalah lebih tinggi. Aritmia, kegagalan jantung 
dan kematian tidak menunjukkan perbezaan. 
Kajian 2 dalam tesis ini merupakan kajian kohot, mengkaji prognosis 
ACS di kalangan pesakit Yemeni pada altitud tinggi dan rendah. Satu ratus 
lima puluh tujuh pesakit ACS (157) dari altitud tinggi dan rendah telah dikaji 
mulai dari waktu kemasukkan ke wad CCU sehingga 12 bulan kemudian. 
Keputusan yang diperolehi kajian 2 menunjukkan bahawa umur purata pesakit 
ACS adalah rendah pada altitud tinggi apabila dibandingkan dengan penduduk 
altitud rendah, Kadar jantung (HR), SBP dan DBP adalah lebih tinggi pada 
altitud tinggi. Pesakit altitud tinggi menunjukkan paras, kreatinin kinase (CK), 
kreatin kinase-isoenzim (CK-MB), darah sel putih (WBC), jumlah kolesterol, 
LDL-C, TG dan paras glukosa rawak (RBG) yang lebih tinggi. Prevalen sejarah 
hyperlipidemia adalah lebih tinggi di antara pesakit altitud tinggi. Fraksi ejeksi 
ventrikel kiri ketika di dalam wad adalah lebih rendah di kalangan pesakit altitud 
tinggi. Penggunaan beta blocker ketika di dalam wad adalah lebih tinggi di 
kalangan pesakit altitud rendah. Penggunaan agen trombolitik, heparin, aspirin, 
peracat enzim penukar angiotensin (ACE-I), nitrat, agen mengurangkan kadar 
lipid, diuretik dan penghalang saluran kalsium adalah sama. Lawatan susulan 
bulan ke-enam menunjukkan nilai tinggi untuk HR, SBP, DBP dan HF untuk 
pesakit altitud tinggi. Lawatan susulan di akhir satu tahun menunjukkan nilai 
tinggi untuk HR, SBP, DBP dan keperluan angiografi diagonostik untuk arteri 
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koronori di kalangan penduduk altitud tinggi. Kegagalan jantung adalah lebih 
kerap dan L VEF mempunyai nilai rendah untuk pesakit altitud tinggi. 
Penggunaan beta blocker adalah lebih tinggi di kalangan pesakit altitud rendah. 
Kegunaan ubat yang lain adalah sama. 
Kajian 3 dalam tesis ini meliputi penyemakan rekod retrospektif untuk 
menyiasat sifat ekokardiografi dan untuk menentukan keterukan oklusi arteri 
koronari ke atas pesakit dari kedua-dua altitud. Sebanyak enam ratus dua 
rekod (602) pesakit ACS yang telah melalui angiografi diagnostik telah disiasat. 
Penemuan kajian 3 menunjukkan bahawa umur purata untuk mengambil ujian 
angiografi koronori adalah lebih muda untuk pesakit altitud tinggi. Pesakit dari 
altitud tinggi mempunyai nilai yang lebih tinggi untuk HR, SBP dan DBP. 
Prevalen riwayat hiperlipidemia dan CAD adalah lebih tinggi di kalangan pesakit 
altitud tinggi. Bilangan riwayat OM dan merokok adalah tinggi dengan "border 
line significance" di antara pesakit altitud tinggi. Fraksi ejeksi ventrikel kiri 
mempunyai nilai Satu yang rendah untuk pesakit altitud tinggi. Oklusi tiga 
saluran adalah lebih kerap untuk pesakit altitud tinggi. Oklusi satu saluran pula 
adalah lebih kerap untuk pesakit altitud rendah. Pesakit altitud tinggi 
mempunyai frekuensi yang lebih tinggi untuk menghidapi oklusi arteri 
circumflex, "left anterior descending artery" dan arteri koronari kanan. 
Sebagai kesimpulan, di Yemen, ACS berlaku pada peringkat umur yang 
muda pada altitud tinggi. Pesakit ACS altitud tinggi menunjukkan prevalen 
risiko kardiovaskular yang lebih tinggi. Oklusi koronari dan kesudahan klinikal 
adalah lebih teruk untuk pesakit altitud tinggi. Penemuan ini menunjukan altitud 
tinggi boleh dianggap salah satu risiko tersendiri ACS. 
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HIGH ALTITUDE AND OTHER RISK FACTORS FOR CORONARY ARTERY 
DISEASE IN YEMEN; PREVALENCE, CLINICAL PRESENTATION, 
COMPLICATIONS AND PROGNOSIS 
ABSTRACT 
The main objectives of this thesis are to estimate the prevalence of risk factors, 
to investigate the clinical presentation, complications, prognosis, 
echocardiographic characteristics and coronary angiography findings among 
ACS patients at high and low altitudes. 
Study 1 was a retrospective review of records aimed at estimating the 
prevalence of risk factors in the ACS patients living at high and low altitudes. It 
was also aimed to investigate the clinical presentation and complications of 
these patients. Seven hundred and sixty eight (768) ACS patients from high and 
low altitudes were studied. Results of study 1 showed that the mean age of 
ACS patients at high altitude was significantly younger. Heart rate, systolic 
blood pressure (SBP) and diastolic blood pressure (OBP) were significantly 
higher at high altitude. High altitude patients were also seen to have 
significantly higher hemoglobin (Hb), hematocrit, white blood cells (WBC), 
creatine kinase (CK), creatine kinase-isoenzyme (CK-MB), total cholesterol, low 
density lipoprotein cholesterol (LDL-C) and triglycerides (TG). The prevalence 
of past history of hyperlipidemia and history of coronary artery disease (CAD) 
were significantly higher for high altitude patients. The prevalence of past 
history of diabetes mellitus (OM) and smoking were higher with border line 
significance for high altitude. Cardiac wall motion abnormalities detected by 
echocardiography was higher for high altitude patients. Left ventricular ejection 
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ventricular E:jection fraction (LVEF) was significantly lower at high altitude. High 
altitude patients were seen to have significantly higher rate of stroke. 
Arrhythmias, heart failure and death did not show any difference. 
Study 2 was a cohort study, aimed at evaluating the prognosis of ACS 
among patients at high and low altitudes. One hundred and fifty seven (157) 
ACS patients from high and low altitudes were evaluated from admission to 
CCU for up to 12 months. Results of study 2 showed that the mean age of ACS 
patients at high altitude was younger. Heart rate, SBP and DBP were higher for 
patients at high altitude. High altitude patients had higher CK-MB, WBC, total 
cholesterol, LDL-C and random blood glucose. The prevalence of past history of 
hyperlipidemia among ACS patients was higher for patients at high altitude. Left 
ventricular ejection fraction during hospitalization was lower for high altitude 
patients. Beta-blocker use was significantly higher at low altitude. Usage of 
thrombolytic agent, heparin, aspirin, angiotensin converting enzyme inhibitor 
(ACE-I), nitrates, lipid lowering agent, diuretics, and calcium channel blocker 
(CCB) were comparable. After six months of follow up, HR, SBP, DBP and 
incidence of heart failure were higher for high altitude patients. At the end of 1 
year follow up, high altitude patients were seen to have higher HR, SBP, DBP 
and have more diagnostic coronary angiography done. Heart failure was more 
frequent among high altitude patients and L VEF was lower for high altitude 
patients. Betq-blocker use was significantly higher at low altitude, the rest of 
medication usage were comparable. 
Study 3 was a retrospective review of records aimed at investigating 
echocardiographic characteristics and severity of coronary artery occlusions 
among high and low altitudes ACS patients. Records of six hundred and two 
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(602) ACS patients from high and low altitudes who underwent diagnostic 
coronary angiography were reviewed. Results of study 3 showed that the mean 
age of high altitude patients who underwent coronary angiography was 
younger. High altitude patients were seen to have higher HR, SBP and DBP. 
The prevalence of past history of hyperlipidemia and history of CAD were 
significantly higher for high altitude patients. Reported family history of CAD 
was significantly higher among low altitude patients. The prevalence of history 
of OM and smoking for patients at high altitude were higher with border line 
significance. Left ventricular ejection fraction was lower for high altitude 
patients. Three vessel occlusions were significantly more common for patients 
at high altitude while single vessel occlusion was significantly more common for 
low altitude patients. High altitude patients were seen to have more occlusions 
in circumflex coronary artery (CX), left anterior descending artery (LAD) and 
right coronary artery (RCA). 
In conclusion, in Yemen, ACS occurs at younger age in high altitude 
residence. High altitude ACS patients also have more prevalent cardiovascular 
risk factors. They also demonstrated more severe coronary lesion and more 
adverse clinical outcome. These findings suggest that high altitude itself should 
be considered as an independent risk factor for ACS. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
Coronary artery disease is defined as a wide spectrum of conditions ranging 
from silent ischemia and exertion-induced angina, through unstable angina, to 
acute myocardial infarction (AMI). Unstable angina occupies the centre of this 
spectrum, causing disability and risk greater than that of chronic stable angina 
but less than that of acute myocardial infarction (AMI) (Braunwald et a/1994., 
Suraj at a/ 2005). Coronary Artery Disease (CAD) is a well-established major 
cause of death and disability in developed countries as well as in developing 
countries (Lopez and Murray., 1998). 
Coronary Artery Disease continues to be a leading cause of morbidity 
and mortality among adults in Europe and North America (McGovern et a/., 
1996). British Heart Foundation estimated that 2.6 million in the UK have had 
coronary artery disease (British Heart Foundation., 2006). Coronary artery 
disease alone is the most common cause of death in Europe, accounting for 
nearly 2 million deaths each year (British Heart Foundation., 2000). According 
to the WHO, in 2001 there were 7.2 million deaths from coronary artery disease 
globally, and this is expected to increase to 11.1 million deaths in 2020 (WHO., 
2002). 
Although cardiovascular mortality has been diminishing for the past 
decades in all of Western Europe and North America, it is still one of the major 
contributors to mortality, especially premature death (Tunstall et a/., 1999). 
Despite declines in developed countries, both CAD mortality and the 
prevalence of CAD risk factors continue to rise rapidly in developing countries 
(Okrainec., 2004). Traditional risk factors for CAD are age, male sex, family 
history, diabetes mellitus, dyslipidemia, hypertension, obesity, and tobacco 
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smoking. These risk factors are useful for assessment of each individual's 
cardiovascular risk (Spence et a/., 1999). Many other risk factors however, are 
still under scientific scrutiny (WHO., 1988), Several studies suggested that 
classical risk factors partially explain the prevalence of CAD (Menotti et a/ 
1993., AI-Nuaim 1993., WHO 1994). 
Geographical variations in CAD prevalence and mortality have been 
reported both between and within countries (Zareba eta/., 1994). Geographical 
variations in CAD have been explained by variations in major risk factors and/or 
socioeconomic factors in a number of studies but, some variations tend to 
remain even after controlling for these factors. Disparities in cardiovascular 
outcomes across geographical regions are common, and yet not well 
understood (Moise and Jacobzone., 2003). Despite reported sizable 
geographical variations in CAD occurrence and outcome, only a few 
environmental contributors have been identified. Differences in environmental 
and genetic factors lead to differences in the incidence of CAD worldwide 
(Dawber et a/1996., Kerhuis et a/2000). 
One environmental risk factor which may contribute to CAD is high 
altitude. Evidence for this is so far conflicting. Many studies have examined 
some risk factor profile for CAD in high altitude and low altitude population with 
conflicting findings, (MiraKhimov and Rafibekae 1985., Wolf et a/1994., Sharma 
1990., Temte 1996., Pasini et a/1999., Fujimoto et a/1989 Fiori et a/2000., 
Dominguez et a/2000., Jefferson et a/2002., Nikos et a/2005). 
There are a few studies investigating a possible association between 
altitude residence and mortality from CAD. Those that have been undertaken 
did not fully adjust for potential confounders and were conducted in 
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heterogeneous populations consisting of different ethnic subgroups (Mortimer et 
a/1977., Buechley et a/1979, Roberts et a/1979., Wei-Ching et a/2005). It 
has been postulated that the residual variation may be due to differences in 
environmental factors. 
Hypoxia at high altitude is associated with increase in myocardial work 
which leads to increase the oxygen demand for cardiac muscle which may 
precipitate the presence of angina and development of myocardial infarction. 
Cardiovascular effects of high altitude residence on coronary artery disease 
patients raise a question concerning the tolerability of exposure to high altitude. 
Firstly, the observed increase in the numbers of patients admitted with ACS, all 
over the world, as well as in the Middle-East has raised many questions about 
the precipitating factors and etiological background. Epidemiological data have 
shown the importance of traditional and other risk factors in the pathogenesis of 
atherosclerosis. Recent studies, however suggest that the pattern of risk factor 
profile may differ according to age, gender, racial, geographical and 
environmental factors. However, only a few studies have investigated the effect 
of altitude on the prevalence of risk factors for CAD. The populations which 
were investigated were of heterogeneous ethnicity. This provides us with the 
incentive to further investigate the association of CAD risk factors and altitudes 
in a country like Yemen where the population is predominantly of the same 
ethnicity. Such study will enable us to establish the independent role of altitude 
on the prevalence of risk factors for CAD. One way of doing this is to study 
patients with documented cardiovascular events. This will not only allow us to 
investigate altitude as an independent risk factor for CAD but will also enable us 
to study whether differences exist in clinical characteristics of patients with 
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established CAD at different altitudes. Secondly, the effect of altitude on the 
prognosis of acute coronary syndrome has been never studied. There was only 
one study which studied the effect of altitude in on CAD mortality among 
general population. However it was done among a heterogeneous population 
and the altitude studied was not high altitude enough (980 meters above sea 
level), (Nikos eta/., 2005). Thirdly, the relation between altitude residence and 
the severity of coronary arteries occlusion has not been studied before. The 
effect of altitude on the prognosis of ACS poses some interesting questions. 
Does high altitude increase the risk factors for coronary artery disease? Does 
hypoxia at high altitude increases ischemia, or provokes the transition to 
unstable syndromes such as unstable angina or acute myocardial infarction? 
Finally, does living at a high altitude increase the severity and risk of mortality 
among ACS patients and should altitude be taken into account when comparing 
cardiovascular risk for ACS? 
A lack of data provides incentives to further investigate the association of 
risk factors profile for CAD, mortality, prognosis and different altitudes residence 
in a country such as Yemen where the population are predominantly of the 
same ethnicity (Arab), and its capital is located at high altitude of 2400 meters 
above sea level as well as the second capital located at low altitude region (sea 
level). 
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1.2 Aim of studies in this thesis 
1. To investigate the effect of altitude on the prevalence of risk factors, 
clinical presentation, complications and prognosis of acute coronary 
syndrome patients at high and low altitude regions in Yemen. 
2. To investigate the effect of altitude on the severity of coronary arteries 
occlusions at different altitudes. 
1.3 Objectives 
1. To estimate the prevalence of risk factors of ACS Yemeni patients at 
high versus low altitude regions. 
2. To investigate the clinical presentation and complications of ACS during 
hospitalization among high versus low altitude patients. 
3. To evaluate the effect of altitude on prognosis of ACS followed up for one 
year. 
4. To investigate the effect of the altitude on echocardiographic characters 
and severity of coronary arteries occlusions among high and low altitude 
ACS patients. 
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CHPTER 2 
LITERATURE REVIEW 
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2.1 Definition of acute coronary syndrome 
Acute coronary syndrome is defined as a spectrum of clinical manifestations 
include unstable angina, acute myocardial infarction and to some extent, 
sudden cardiac death (Kristain et a/2001). 
2.2 Diagnosis of acute coronary syndrome 
2.2.1 Diagnostic guidelines 
The World Health Organization criteria for the diagnosis of acute coronary 
syndrome required at least two of the following three elements to be present; 
AMI with ST elevation (typical symptoms or ECG with ST elevation and raised 
CK-MB or troponin), AMI without ST elevation (typical symptoms or ECG 
without ST elevation and raised CK-MB or troponin) and unstable angina 
(symptoms or ECG indicative of ischemia, with normal enzymes) (WHO 
database, 2003., Gomes et a/2005). 
There is considerable variability in the pattern of presentation of ACS 
with respect to these three elements. ST -segment elevation and Q waves on 
the ECG, two features that are highly indicative of AMI, are seen in only about 
half of AMI cases on presentation (Goldberg eta/., 1988). Approximately one-
fourth of patients with AMI do not present with classic chest pain, and the event 
would go unrecognized unless an ECG were recorded fortuitously in temporal 
proximity to the infarction or permanent pathological Q waves are seen on later 
tracings (Kannel., 1 987). Non-diagnostic ECG's are recorded in approximately 
half of patients presenting to emergency departments with chest pain 
suspicious for AMI who ultimately are shown to have an AMI (Gibler et a/., 
1990). Among patients admitted to the hospital with a chest pain syndrome, 
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fewer than 20 per cent are subsequently diagnosed as having had an AMI 
(Gilber eta/., 1992). Therefore, in the majority of patients, clinicians must obtain 
serum cardiac marker measurements at periodic intervals to either establish or 
exclude the diagnosis of AMI (Sacks., 1994). Such measurements may also be 
useful for a rough quantitation of the size of infarction (Murray and Alpert., 
1994). 
2.2.2 Clinical presentation 
2.2.2.1 Prodromal symptoms 
Despite recent advances in the laboratory detection of AMI, history remains of 
substantial value in establishing a diagnosis (Huggins et a/., 1996). The 
prodrome is usually characterized by chest discomfort, resembling classic 
angina pectoris, but it occurs at rest or with less activity than usual and can 
therefore be classified as unstable angina. However, the latter is often not 
disturbing enough to induce patients to seek medical attention. Among patients 
who are hospitalized for unstable angina, fewer than 10 per cent develop AMI. 
Of the patients with AMI presenting with prodromal symptoms of unstable 
angina, approximately one-third have had symptoms from 1 to 4 weeks before 
hospitalization. In the remaining two-thirds, symptoms predated admission by 1 
week or less, with one-third of these patients having had symptoms for 24 hours 
or less (Harper et a/., 1979). A feeling o,f general malaise or frank exhaustion 
often accompanies other symptoms preceding AMI. 
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2.2.2.2 Nature of the pain 
The pain of AMI is variable in intensity; in most patients it is severe and in some 
instances intolerable. The pain is prolonged, usually lasting for more than 30 
minutes and frequently for a number of hours. The discomfort is described as 
constricting, crushing, or compressing. The pain is usually retrosternal in 
location, spreading frequently to both sides of the anterior chest, with 
predilection for the left side. Often the pain radiates down the ulnar aspect of 
the left arm, producing a tingling sensation in the left wrist, hand, and fingers. 
Some patients note only a dull ache or numbness of the wrists in association 
with severe substernal or precordial discomfort. However, it is generally much 
more severe, lasts longer, and is not relieved by rest and nitroglycerin. 
In some patients, particularly the elderly, AMI is manifested clinically not by 
chest pain but rather by symptoms of acute left ventricular failure and chest 
tightness or by marked weakness or frank syncope. These symptoms may be 
accompanied by diaphoresis, nausea, and vomiting (Muller eta/., 1990). 
The pain of AMI may have disappeared by the time the physician first 
encounters the patient (or the patient reaches the hospital), or it may persist for 
many hours. Opiates, in particular, morphine, usually relieve the pain. Both 
angina pectoris and the pain of AMI are thought to arise from nerve endings in 
ischemic or injured, but not necrotic, myocardium (Malliani and Lombardi., 
1982). Thus, in AMI, stimulation of nerve fibers in an ischemic zone of 
myocardium surrounding the necrotic central area of infarction probably gives 
rise to the pain. Pain often disappears suddenly and completely when blood 
flow to the infarct territory is restored. In patients in whom re-occlusion occurs 
after thrombolysis, pain recurs if the initial reperfusion has left viable 
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myocardium. Thus, what has previously been thought of as the "pain of 
infarction," sometimes lasting for many hours, probably represents pain caused 
by ongoing ischemia. The recognition that pain implies ischemia and not 
infarction heightens the importance of seeking ways to relieve the ischemia, for 
which the pain is a marker. 
2.2.2.3 Other symptoms 
Nausea and vomiting occur in more than 50 per cent of patients with transmural 
Ml and severe chest pain (Ingram eta/., 1980). It is due to activation of the 
vagal reflex or to stimulation of left ventricular receptors as part of the Bezold-
Jarisch reflex. These symptoms occur more commonly in patients with inferior 
Ml than in those with anterior MI. Occasionally a patient complains of diarrhea 
or a violent urge to evacuate the bowels during the acute phase of MI. Other 
symptoms include feelings of profound weakness, dizziness, palpitations, cold 
perspiration, and a sense of impending doom. On occasion, symptoms arising 
from an episode of cerebral embolism or other systemic arterial embolism are 
the first signs of AMI. The aforementioned symptoms may or may not be 
accompanied by chest pain. 
Sigurdsson eta/., (1995) reported that more than 20 percent of non fatal 
myocardial infarction are unrecognized by the patient and are discovered only 
on subsequent routine electrocardiographic tests. It also reported that 
unrecognized or silent myocardial infarction occurs more commonly in diabetic 
and hypertensive patients. 
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2.3 Investigations and procedures 
2.3.1 Electrocardiogram (ECG) 
A serial standard 12-lead ECG remain a clinically useful method for the 
detection and localization of acute myocardial infarction (Murray and 
Alpert., 1994). 
Parameters of ECG with suspected ACS are ST-elevation with or without Q 
wave in two leads at least, pathological Q-wave, ST depression, peaked or 
hyper acute T waves, T wave flattening or inversion with or without ST segment 
depression, R wave changes, left bundle branch block and arrhythmias. 
2.3.2 Laboratory finding in ACS 
2.3.2.1 Serum cardiac markers 
Serum cardiac marker determinations play a vital role in the diagnosis of ACS. 
Serum markers such as aspartate transaminase (AST), lactate dehydrogenase, 
(LDH) and lactate dehydrogenase subforms no longer are used because they 
lack cardiac specificity and their delayed elevation precludes early diagnosis 
(Braunwald eta/., 2001 ). 
2.3.2.1.1 Creatine kinase (CK) 
It is an enzyme that is found in striated muscle and tissues of the brain, kidney, 
lung, and gastrointestinal tract. This widely available marker has low sensitivity 
and specificity for cardiac damage. Furthermore, CK levels may be elevated in 
a number of noncardiac conditions, including trauma, seizures, renal 
insufficiency, hyperthermia, and hyperthyroidism. The serum CK level rises 
within three to eight hours after myocardial injury, peaks by 12 to 24 hours, and 
returns to baseline within three to four days (Karras eta/., 2001 ). A serum CK 
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level may be used as a screening test to determine the need for more specific 
testing. Although CK commonly was measured serially (along with CK-MB) at 
the time of hospital admission and six to 12 hours after admission, this marker 
largely has been replaced by cardiac troponins and CK-MB (Braunwald at a/., 
2001). 
2.3.2.1.2 CK-MB isoenzyme 
CK-MB is one of the most important myocardial markers (in spite of not being 
altogether cardiac-specific), with well-established roles in AMI and in monitoring 
reperfusion during thrombolytic therapy following AMI (Apple et a/., 1994 ). In 
AMI, plasma CK-MB typically rises some 4-6 hours after the onset of chest 
pains, peaks within 12-24 hours, and returns to baseline levels within 24-48 
hours. The pattern of serial CK-MB determinations is more informative than a 
single determination: one CK-MB measurement, even when taken at an 
appropriate time, cannot definitively confirm or rule out the occurrence of AMI. 
Accordingly, it has been recommended that CK-MB be measured on admission 
to the emergency room and at intervals thereafter (eg, at 3-hour intervals over a 
6- to 9-hour period in patients with nonspecific electrocardiogram changes; 1, 2 
or at 6- to 8-hour intervals over a 24-hour period (Apple eta/., 1994). 
Like the CK level, the peak CK-MB level does not predict infarct size; 
however, it can be used to detect early re-infarction (Karras., 2001 ). Three 
isoenzymes of CK (MM, BB, and MB) have been identified by electrophoresis. 
Extracts of brain and kidney contain predominantly the BB isoenzyme, skeletal 
muscle contains principally MM but does contain some MB (1 to 3 per cent), 
and both MM and MB isoenzymes are present in cardiac muscle (Tsung eta/., 
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1986). Serial CK-MB levels commonly are obtained at admission to the 
emergency department and are repeated in six to 12 hours, depending on the 
assay that is used (American College of Emergency Physicians 2000). CK-MB 
isoform may be further characterized into isoforms. CK-MB2 is found in 
myocardial tissue, and CK-MB1 is found in plasma. The CK-MB isoform assay 
takes about 25 minutes to perform (Puleo eta/., 1989). A CK-MB2 level greater 
than 1 U per L in combination with a sub-form ratio greater than 1.5 suggests 
myocardial injury (Bock eta/., 1999). 
2.3.2.1.3 Cardiac troponins 
The troponin complex consists of three subunits that regulate the calcium-
mediated contractile process of striated muscle (Katus eta/., 1992). These are 
troponin C which binds Ca++, troponin I which binds to actin and inhibits actin-
myosin interactions and troponin T which binds to tropomyosin, thereby 
attaching the troponin complex to the thin filament (Katus eta/., 1991). Troponin 
T and I generally have similar sensitivity and specificity for the detection of 
myocardial injury. Unlike troponin I levels, troponin T levels may be elevated in 
patients with renal disease, polymyositis, or dermatomyositis. The cardiac 
troponins typically are measured at emergency department admission and 
repeated in six to 12 hours (American College of Emergency Physicians. 2000). 
Patients with a normal CK-MB level but elevated troponin levels are considered 
to have sustained minor myocardial damage or micro-infarction, whereas 
patients with elevations of both CK-MB and troponins are considered to have 
had acute myocardial infarction. The cardiac troponins may remain elevated up 
to two weeks after symptom onset, which makes them useful as late markers of 
recent acute myocardial infarction (Braunwald et a/., 2001). An elevated 
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troponin T or I level is helpful in identifying patients at increased risk for death or 
the development of acute myocardial infarction (Karras eta/., 2001 ). Increased 
risk is related quantitatively to the serum troponin level. The troponins also can 
help identify low-risk patients who may be sent home with close follow-up. In a 
study of 773 patients presenting to an emergency department with acute chest 
pain, those with a normal or nearly normal ECG and a normal troponin I test six 
hours after admission had a very low risk of major cardiac events (0.3 percent) 
during the next 30 days. Bedside troponin assays have been developed. 
2.3.2.1.4 Myoglobin 
Myoglobin is a low-molecular-weight protein that is present in both cardiac and 
skeletal muscle. It can be detected in the serum as early as two hours after 
myocardial necrosis begins. Myoglobin has low cardiac specificity but high 
sensitivity, which makes it most useful for ruling out myocardial infarction if the 
level is normal in the first four to eight hours after the onset of symptoms 
(Braunwald eta/., 2001). Time changes in the myoglobin value also can be 
extremely helpful. Combining a doubling of the baseline myoglobin level at two 
hours after symptom onset with an abnormal myoglobin test at six hours v 
symptom onset increases the sensitivity to 95 percent at six hours (Decker et 
a/., 2006). Myoglobin should be used in conjunction with other serum markers, 
because its level peaks and falls rapidly in patients with ischemia. 
2.3.3 Hematological functions 
2.3.3.1 Leukocytes 
Acute coronary syndrome is usually accompanied by leukocytosis, which is 
related to the necrotic process and its magnitude and to elevated glucocorticoid 
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levels. Activation of neutrophils may produce important intermediates, such as 
leukotriene B4 and oxygen free radicals that have important microcirculatory 
effects (Engler eta/,. 1983). 
2.3.3.2 Hemoglobin and hematocrit 
Clinical and epidemiological. studies suggest that several hemostatic and 
hemorheological factors (e.g., fibrinogen, Factor VII, plasma viscosity, 
hematocrit, red blood cell aggregation, total white cell count) are involved in the 
pathophysiology of athe~osclerosis and also play an integral role in acute 
thrombotic events (Koenig and Erns., 1992). An increase in blood viscosity also 
occurs in patients with AMI. During the first few days after infarction, this is 
mainly attributable to hemoconcentration, but later the increases in plasma 
viscosity and red cell aggregation correlate with elevated serum concentrations 
of alpha2 globulin and fibrinogen, which are nonspecific reactions to tissue 
necrosis and are also responsible for the elevated sedimentation rate 
characteristic of AMI (Hershberg eta/., 1972). The high values of blood viscosity 
indices are observed most frequently in patients with complications such as left 
ventricular failure, cardiogenic shock, and thromboembolism. 
2.3.4 Lipid profile 
These are often determined in patients with AMI. However, the results may be 
misleading because numerous factors that can alter the values are operating at 
the time of the patient's admission to the hospital. Serum triglycerides are 
affected by caloric intake, intravenous glucose, and recumbency. During the 
first 24 to 48 hours after admission, total cholesterol and HDL cholesterol 
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remain at or near baseline values but generally fall precipitously after that. The 
fall in HDL cholesterol after AMI is greater than the fall in total cholesterol; thus, 
the ratio of total cholesterol to HDL cholesterol is no longer useful for risk 
assessment early after Ml (Ronnemaa et a/., 1980). In review of the revised, 
more aggressive guidelines for management of hyperlipidemia in patients with 
clinical manifestations of coronary artery disease (The Third Report of the 
National Cholesterol Education Program., 2001), a lipid profile should be 
obtained on all AMI patients who are admitted within 24 to 48 hours of 
symptoms. 
2.3.5. Echocardiography 
2.3. 5.1 Two dimensional echocardiography 
The relative portability of echocardiographic equipment makes this technique 
ideal for the assessment of patients with AMI hospitalized in the coronary care 
unit or even in the emergency department before admission (Nishimura., 1996). 
In patients with chest pain compatible with AMI but with a non-diagnostic ECG, 
the finding on echocardiography of a distinct region of disordered contraction 
can be helpful diagnostically because it supports the diagnosis of myocardial 
ischemia (Hepner and Armstrong., 1995). Echocardiography is also useful in 
evaluating patients with chest pain and a non-diagnostic ECG who are 
suspected of having an aortic dissection. The identification of an intimal flap 
consistent with an aortic dissection is a crucial observation because it 
represents a major contraindication to thrombolytic therapy. Areas of abnormal 
regional wall motion are observed almost universally in patients with AMI, and 
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the degree of wall motion abnormality can be categorized with a 
semiquantitative wall motion score index (Segar eta/., 1992). 
2.3.5.2 Doppler echocardiography 
This technique allows for assessment of blood flow in the cardiac chambers and 
across cardiac valves. Used in conjunction with two-dimensional 
echocardiography, it is helpful in detecting and assessing the severity of mitral 
or tricuspid regurgitation following AMI (Harrison and Bashore., 1995). 
Identification of the site of acute ventricular septal rupture, as well as 
quantification of shunt flow across the resulting defect, is also possible (Smyllie 
eta/., 1990). 
2.3.6 Stress testing 
Stress testing is a mean of further assessing for the presence of flow-limiting, 
functionally significant coronary artery disease. The preferred method of 
cardiovascular stress testing is exercise, utilizing a treadmill or bicycle. Through 
aerobic exercise, one achieves a greater rate pressure product and therefore 
greater cardiovascular stress. This permits an assessment of an individual's 
functional capacity, providing prognostic data utilizing the sole parameter of 
attained metabolic equivalents or oxygen utilization. Heart rate recovery, the 
rapidity of the heart rate to decline after exercise cessation, is also an important 
prognostic parameter. Exercise-induced arrhythmias are also commonly 
observed and provide information concerning efficacy of heart arrhythmias and 
also may represent the initial manifestation of CAD. 
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The most common agent used for pharmaclogic stress testing is dobutamine. 
Dobutamine acts as beta-receptor 1 and 2 agonist, increasing myocardial 
contractility, heart rate, and inducing peripheral vasodilation; in sum raising 
myocardial oxygen demand. It is usually combined with echocardiography. 
Dobutamine echocardiography is useful in assessing for the presence of 
functionally significant obstructive coronary artery disease and also in assessing 
a post-myocardial infarction patient. Utilizing echocardiography, be it combined 
with exercise or dobutamine, the physician interpreter is focusing upon the 
global and regional myocardial response to cardiovascular stress. Under normal 
circumstances, the end systolic left ventricular volume at peak stress diminishes 
and myocardial thickening is symmetrically enhanced. When abnormal, a 
regional decrement of myocardial thickening is observed, supporting inducible 
myocardial ischemia. In the presence of advance multivessel coronary artery 
disease, the left ventricle actually dilates and a marked reduction in global 
myocardial thickening 1s observed. Dobutamine echocardiography is 
additionally useful for the assessment of myocardial viability in patients with 
known ischemic left ventricular systolic dysfunction. In this circumstance, when 
contemplating myocardial revascularization, it is important to determine, pre-
procedure, what areas are dysfunctional yet alive versus dysfunctional with 
irreversible scarring. 
2.3. 7 Coronary arteriography 
Cardiac catheterization is currently the "gold standard" for determining the 
presence of obstructive coronary artery disease. A cardiac catheterization yields 
a two-dimensional rendering of the coronary artery circulation. To assist in 
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circumventing the limitations of a two-dimensional depiction of three-
dimensional anatomy, multiple views from varying angles are obtained as a 
standard. It is exceedingly important to visuali:c:e each coronary artery segment 
from at least two orthogonal views. Coronary artery plaque formation is usually 
eccentric in location, not a smooth cylindrical encroachment upon the coronary 
artery lumen, and variable in appearance from different vantage points. This 
eccentricity can lead to both under- and overestimation of coronary artery 
disease severity, necessitating a methodical approach to view acquisition. 
A more accurate assessment of coronary arterial lumen is by assessing 
the cross-sectional area of the coronary artery, expressed as a percentage 
obstruction. This requires the direct visualization of the coronary artery from 
within the lumen. This limitation has proved the catalyst for the development of 
intravascular ultrasound. During this procedure, a small flexible ultrasound 
probe is threaded down the coronary artery. The images are obtained in real 
time, with a percentage lumen diameter readily calculated. For coronary artery 
lesions not well seen on routine coronary artery arteriography, this has been an 
extremely helpful technique providing clarification as to disease severity. 
Additionally, intravascular ultrasound can help guide the interventional 
cardiologist as to device selection prior to performing percutaneous coronary 
artery revascularization. A subset of patients where intravascular ultrasound 
has proven extremely helpful is the cardiac transplantation population. These 
patients develop a coronary arteriopathy where compromise of the coronary 
arterial lumen is smooth, cylindrical, and diffuse throughout the coronary arterial 
tree. A routine cardiac catheterization may demonstrate the somewhat smaller 
coronary arteries with a distal, tapered appearance. Without a normal reference 
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segment, it is not possible to accurately ascribe a percentage of lumen 
compromise. The indications for cardiac catheterization in patients with CAD 
were presented by the ACC/AHA guidelines (Stary eta/., 1994). 
2.4 Pathophysiology of ACS 
Acute coronary syndrome is a spectrum of clinical manifestations ranging from 
unstable angina, acute myocardial infarction to some extent, sudden cardiac 
death (Kristian et a/., 2001 ). This spectrum shares common underlying 
pathophysiological mechanisms. The central features consist of fissuring or 
erosion of atheromatous plaque with superimposed platelet aggregation and 
thrombosis. This is complicated by microfragmentation and distal embolisation 
with alterations in vascular tone in affected myocardium. As a consequence, 
clinical manifestations are dependent upon the severity of obstruction in the 
affected coronary artery, the presence or absence of collateral perfusion, and 
the volume and myocardial oxygen demand within the affected territory. Thus, 
the spectrum extends from abrupt occlusion with acute ischemia leading to 
infarction, through partial coronary obstruction and distal ischemia with minor 
enzyme release (minimal myocardial injury), to non-occlusive thrombosis with 
normal cardiac enzymes (unstable angina), (Fox., 2000). 
Myocardial ischemia occurs when the oxygen supply to the heart is 
deficient in relation to the oxygen need. Oxygen consumption is closely related 
to the physiologic effort. Therefore, the heart must rely primarily on an increase 
in the coronary blood flow for obtaining additional oxygen. A relatively slight 
alteration in coronary luminal diameter below a critical level can produce a large 
decrement in coronary flow, provided that other factors remain constant. When 
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the epicardial coronary arteries are narrowed critically, the intramyocardial 
coronary arterioles dilate in an effort to maintain total flow at a level that will 
avert myocardial ischemia at rest. Hence any condition in which increased HR, 
SBP, DBP occurs in the presence of coronary obstruction tends to precipitate 
IHD due to oxygen needs. Cardiac ischemia results from an imbalance between 
myocardial oxygen supply and demand. Cardiac ischemia is taken as 
myocellular hypoxia or the condition resulting when oxygen supplied to a region 
of heart muscle is insufficient to meet its needs. The clinical phenotype 
accompanying cardiac ischemia has traditionally been subdivided into the IHD 
and ACS. A sudden reduction in coronary flow and hence, myocardial oxygen 
supply, is usually the mechanism of ACS. Here, recent plaque injury (e.g., 
rupture, erosion, hemorrhage), often superimposed on thrombosis and/or micro-
embolism, endothelial dysfunction and heightened smooth muscle reactivity 
abruptly reduce coronary blood flow and lead to acute ischemic myocyte injury 
(Libby and Theroux., 2005). By contrast, an abrupt increase in myocardial 
oxygen demand, in the setting of limited ability to increase myocardial oxygen 
supply, is usually the mechanism of ischemia in the IHD. Disorders of 
coagulation, endothelial and/or smooth muscle cell function, as well as the 
myocardium also play a role (Naghavi eta/., 2003). 
2.4.1 Pathology of coronary atherosclerosis 
Coronary artery disease is a chronic process that begins during adolescence 
and slowly progresses throughout life. Independent risk factors include a family 
history of premature coronary artery disease, smoking, OM, HTN, 
hyperlipidemia, a sedentary lifestyle, and obesity. These risk factors accelerate 
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or modify a complex and chronic inflammatory process that ultimately manifests 
as fibrous atherosclerotic plaque. 
Atherosclerotic lesions develop in medium-sized and large arteries and 
may cause circulation disturbances in the heart, brain and extremities. The first 
step in atherosclerotic process is accumulation of lipoprotein particles which are 
called lipid-laden foam cells in the arterial intima (Stary et a/1994., Kruth 1997). 
These cells are monocyte-derived macrophages which have ingested oxidized 
LDL via their scavenger receptors, probably to protect tissues against toxic 
effects of oxidized LDL. These macrophages are subsequently transformed to 
lipid-laden foam cells. 
These early lesions, fatty streaks, can already be found during childhood 
(Pesonen eta/., 1975). During the following decades early lesions advance, and 
accumulation of lipids, fibrous tissue and inflammatory cells, growth of smooth 
muscle cells and endothelial dysfunction characterize coronary atherosclerosis 
(Stary et a/1994., Ross 1999). Irregular thickenings of the arterial intima restrict 
the lumen of coronary artery and reduce the nourishing blood flow to the 
myocardium. A fibrous cap covers the plaque and separates it from the vascular 
lumen. This cap varies in thickness and content of collagen, smooth muscle 
cells and inflammatory cells (Hansson and Libby., 1998). An atherosclerotic 
plaque, which is prone to rupture, is characterized by a large, lipid-rich 
atheromatous core and a thin fibrous cap, in which both collagen content and 
smooth muscle cell density are reduced. Moreover, the amount of inflammatory 
cells in the plaque is increased (Van der Wal et a/., 1994, Falk et a/ 1995). In 
the event of erosion or rupture of atherosclerotic plaque, exposure of its 
thrombogenic content into the lumen of the coronary artery activates 
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thrombocytes and the coagulation system. Activated thrombocytes aggregate at 
the site of rupture and together with the activated coagulation system, form a 
thrombus, which may partially or even totally occlude the lumen of the coronary 
artery (Falk eta/., 1995). With decreasing or complete cessation of blood flow, 
the myocardium becomes ischemic. As a consequence, the clinical setting of 
ACS can manifest itself in a variety of conditions; namely unstable angina, 
acute myocardial infarction or sudden cardiac death. The relation between 
elevated serum cholesterol and atherosclerosis was first published in the 1930s 
by Muller (Muller., 1939). Since then the causal role of elevated serum 
cholesterol in the pathogenesis of atherosclerosis has been well documented 
(Kannel et a/1992., Pekkanen et a/1992). Further studies have shown that the 
principal causal component in the development of atherosclerosis is LDL 
cholesterol, whereas HDL seems to exert a protective effect (Castelli et a/., 
1992). Smoking, hypertension, diabetes, obesity, physical inactivity and genetic 
inheritance are important risk factors in the progression of primary 
atherosclerosis. 
The second morphologically event in the initiation of atheroma is 
leukocyte recruitment and accumulation. The normal endothelial cell generally 
resists adhesive interactions with leukocytes. However, after initiation of 
hypercholesterolemia, leukocytes adhere to the endothelium between 
endothelial cell junctions to enter the intima, where they begin to accumulate 
lipids and transform into foam cells (Gimbrone et a/., 1995). In addition to the 
monocyte, T lymphocytes also tend to accumulate in early human and animal 
atherosclerotic lesions (Emeson and Robertson 1988., Hansson and Libby 
1995). 
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